Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
(Special Offer
The drug has the potential to continue weight-loss beyond a 52-week limit, according to Amgen
Key Benefits Fast onset + long duration No water needed Dual-mechanism support Convenient ODT format $45.00 / month Quad-Stack Sublingual Four-compound sublingual formula targeting every mechanism of sexual arousal and performance
According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management
US$ 28.46
US$ 27.92
US$ 23.97
US$ 24.65
US$ 24.82
